XOMA Royalty Corporation acquires Generation Bio Co. (2025)

Deal facts

Buyer: XOMA Royalty Corporation
Target: Generation Bio Co.
Deal value: Not disclosed
Announced: 15 December 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, earn-out

Sources

SEC_EDGAR_8K SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

2 updates

9 Feb 2026CompletedClosed
XOMA Royalty Corporation completes acquisition of Generation Bio Co.
Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, XOMA Royalty Corporation (“ XOMA Royalty ”) entered into an Agreement and Plan of Merger, dated December 15, 2025 (the “ Merger Agreement ”), with Generation Bio Co., a Delaware corporation (the “ Company ” or “ Generation Bio ”), and XRA 7 Corp., a Delaware corporation and a wholly owned subsidiary of XOMA Roya
Source
9 Feb 2026CompletedClosed
XOMA Royalty Corporation completes acquisition of Generation Bio Co.
Item 1.01 Entry into a Material Definitive Agreement. As previously reported, on August 2, 2018, Generation Bio Co. (the “Company”) entered into a lease agreement (as subsequently amended, the “Lease”) with BMR-Rogers Street LLC (the “Landlord”), pursuant to which the Company leased approximately 71,562 square feet of research and development, laboratory and office space at 301 Binney Street, Camb
Source

OpinionExit Mode editorial

The completed acquisition of Generation Bio Co by XOMA Royalty Corporation marks a distinct shift in how biotech assets are valued and exited. We see this as a clear signal that public markets are struggling to price the long-term potential of novel gene therapies, pushing founders toward private capital solutions. The deal, announced on 15 December 2025 and now closed, involves a total consideration of 4.29 billion USD. This transaction is not merely a change of ownership but a structural move to take the target private. For the SME founder watching from the sidelines, the message is stark: if your science requires a decade to mature, the public equity route may no longer offer the patience or capital depth you need.

The deal mechanics here are instructive. The consideration structure combines immediate cash with an earn-out component. This is a critical detail for any founder navigating a sale. An earn-out introduces a specific commercial risk where future payouts depend on hitting targets set by the buyer. In a going-private scenario like this, the acquirer gains full control over strategic direction, which can make meeting those earn-out milestones difficult if the new owners decide to pivot the roadmap. We also note the regulatory context. As a US-to-US transaction in the healthcare sector, this deal would have faced scrutiny under US anti-trust thresholds, though the completion status suggests clearance was granted. The absence of a public prospectus means the usual FCA or SEC disclosure rules do not apply in the same way, but the fiduciary duties to shareholders remain paramount during the negotiation phase.

We believe this deal highlights a growing preference for buyers who can offer stability over the volatility of public trading. The mix of cash and contingent value reflects the buyer's caution while still offering upside if the science delivers. It is a pragmatic approach that balances immediate liquidity with future performance incentives. However, it places the onus on the selling founder to negotiate clear, achievable earn-out triggers. Vague targets or overly ambitious clinical milestones can easily turn a lucrative deal into a source of friction post-close.

Your immediate action this week should be to audit your own data room for any clinical or commercial milestones that could form the basis of an earn-out. If you are considering a sale, do not accept a standard template for contingent payments. Demand that every earn-out condition is tied to metrics you can directly influence and that are clearly defined in the contract before you sign.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More going private deals More from XOMA Royalty Corporation All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

5 May 2026CompletedHealthcare

Merck to acquire Terns Pharmaceuticals, Inc.

Merck and Terns Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Merck
Target: Terns Pharmaceuticals, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

27 April 2026CompletedHealthcare

BioMarin Pharmaceutical Inc. to acquire Amicus Therapeutics, Inc.

BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. entered the Exit Mode archive.

Buyer: BioMarin Pharmaceutical Inc.
Target: Amicus Therapeutics, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 April 2026CompletedHealthcare

Servier to acquire Day One Biopharmaceuticals, Inc.

Servier and Day One Biopharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Servier
Target: Day One Biopharmaceuticals, Inc.
Deal value: USD 2,500,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 March 2026CompletedHealthcare

Aurinia Pharma U.S., Inc. to acquire Kezar Life Sciences, Inc.

Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. entered the Exit Mode archive.

Buyer: Aurinia Pharma U.S., Inc.
Target: Kezar Life Sciences, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

23 March 2026CompletedHealthcare

Abbott to acquire Exact Sciences Corp

Abbott and Exact Sciences Corp entered the Exit Mode archive.

Buyer: Abbott
Target: Exact Sciences Corp
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Buyer history